Tobrate™ (oral tobramycin tablet) is being evaluated for its potential to treat uncomplicated urinary tract infections (uUTI), a highly prevalent infection affecting approximately 10 million women in the United States each year.
There are several antibiotics available to treat uUTI, however antibiotic resistance is a growing issue, in turn causing current uUTI treatments to become less efficacious. Tobramycin, which has minimal resistance issues, is available in a variety of dosage forms, however no oral formulation exists on the market.
An oral formulation of tobramycin offers an attractive alternative to available first-line treatments that are now less effective due to antibiotic resistance.
Tobrate has been granted QIDP and fast track status by the FDA. The program has completed a Phase 1 safety study and is currently in formulation optimization.